RecruitingNCT03953014

Pharmacogenetics of Antidepressant-Induced Disinhibition

Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study

Sponsor

University of Calgary

Enrollment

120 participants

Start Date

Jan 2, 2019

Study Type

OBSERVATIONAL

Conditions

Major Depressive Disorder Anxiety Disorders Antidepressant Drug Adverse Reaction Obsessive-Compulsive Disorder

Summary

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Eligibility

Min Age: 6 YearsMax Age: 17 Years

Inclusion Criteria4

Aged 6 - 24 years
Medical records available
Diagnosis of MDD, anxiety disorder, or OCD
Current or past history of SSRI therapy

Exclusion Criteria4

Inability of parent/legal guardian to give informed consent
Inability of the child to give informed assent
Unwillingness of child to provide saliva sample for genetic analysis
Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.